Healthcare
Exclusive insider sentiment analysis for the Healthcare sector. Track real-time Director purchases and institutional money flow to identify high-conviction opportunities before the market reacts.
| Filing Date | Trade Date | Ticker | Company Name | Reporting Person | Relationship | Industry | Type | Price | Qty | Total, $ | Owned After | Change, % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-07-16 01:27 | 2026-07-15 | PSNL | Personalis, Inc. | Chen Richard | Officer; President and CMO | Diagnostics & Research | OPT+S | $15.15 | 100,000 | $1,515,000 | 173,880 | -36.5% |
| 2026-07-16 01:05 | 2026-07-13 | NTRA | Natera, Inc. | Sheena Jonathan | Director, Other | Diagnostics & Research | SALE | $265.68 | 3,150 | $836,898 | 246,202 | -1.3% |
| 2026-07-16 00:58 | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Officer; Chief Medical Officer | Biotechnology | OPT+S | $27.28 | 20,407 | $556,672 | 51,384 | -28.4% |
| 2026-07-16 00:58 | 2026-07-13 | MLYS | Mineralys Therapeutics, Inc. | Congleton Jon | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $27.24 | 10,700 | $291,441 | 603,621 | -1.7% |
| 2026-07-15 23:50 | 2026-07-13 | FULC | Fulcrum Therapeutics, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $3.57 | 249,946 | $891,057 | 6,913,329 | +3.8% |
| 2026-07-15 23:36 | 2026-07-15 | ORKA | Oruka Therapeutics, Inc. | Goncalves Joana | Officer; Chief Medical Officer | Biotechnology | OPT+S | $86.28 | 7,000 | $603,938 | 32,718 | -17.6% |
| 2026-07-15 21:00 | 2026-07-14 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $526.83 | 9,500 | $5,004,909 | 40,513 | -19.0% |
| 2026-07-15 20:31 | 2026-07-13 | OMDA | Omada Health, Inc. | Cook Steven L. | Officer; Chief Financial Officer | Health Information Services | OPT+S | $24.00 | 5,800 | $139,206 | 187,209 | -3.0% |
| 2026-07-15 20:33 | 2026-07-13 | OMDA | Omada Health, Inc. | Gracey Craig | Officer; Chief Accounting Officer | Health Information Services | OPT+S | $24.00 | 1,041 | $24,984 | 15,441 | -6.3% |
| 2026-07-15 20:38 | 2026-07-13 | BLLN | BillionToOne, Inc. | Tsao David | Director, Officer; Chief Technology Officer | Diagnostics & Research | OPT+S | $124.88 | 20,000 | $2,497,698 | 1,000 | -95.2% |
| 2026-07-15 20:38 | 2026-07-13 | BLLN | BillionToOne, Inc. | ten Bosch John Roderick | Officer; SVP of Laboratory Operations | Diagnostics & Research | SALE | $125.46 | 4,251 | $533,330 | 29,301 | -12.7% |
| 2026-07-15 20:40 | 2026-07-14 | BCDA | BioCardia, Inc. | Altman Peter | Director, Officer; President and CEO | Biotechnology | BUY | $0.87 | 4,300 | $3,754 | 368,385 | +1.2% |
| 2026-07-15 20:15 | 2026-07-14 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $40.00 | 8,210 | $328,437 | 539,817 | -1.5% |
| 2026-07-15 20:05 | 2026-07-13 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% owner | Biotechnology | BUY | $73.64 | 1,695 | $124,819 | 493,936 | +0.3% |
| 2026-07-15 19:36 | 2026-07-13 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. | HRT FINANCIAL LP | 10% owner | Drug Manufacturers - Specialty & Generic | SALE | $4.48 | 83,149 | $372,707 | 0 | -100.0% |
| 2026-07-15 17:08 | 2026-07-13 | PHVS | Pharvaris N.V. | Modig Berndt | Director, Officer; Chief Executive Officer | Biotechnology | SALE | $34.97 | 2,292 | $80,154 | 132,917 | -1.7% |
| 2026-07-15 16:10 | 2026-07-09 | RDGL | VIVOS INC | Weeks Brad Allan | Officer; President | Medical Devices | BUY | $0.08 | 60,000 | $4,800 | 1,379,654 | +4.5% |
| 2026-07-15 15:43 | 2026-07-15 | RDGL | VIVOS INC | Korenko Michael K | Director, Officer; CEO AND PRESIDENT | Medical Devices | BUY | $0.06 | 200,000 | $11,420 | 11,285,090 | +1.8% |
| 2026-07-15 13:33 | 2026-07-14 | STIM | Neuronetics, Inc. | Chernett Jorey | 10% owner | Medical Devices | BUY | $1.78 | 35,000 | $62,300 | 10,588,988 | +0.3% |
| 2026-07-15 01:25 | 2026-07-10 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $303.18 | 60,218 | $18,256,809 | 0 | -100.0% |
| 2026-07-15 01:26 | 2026-07-14 | ONC | BeOne Medicines Ltd. | OYLER JOHN | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $305.95 | 145,861 | $44,626,421 | 0 | -100.0% |
| 2026-07-14 23:59 | 2026-07-13 | LQDA | Liquidia Corp | Boyle Dana | Officer; Chief Accounting Officer | Biotechnology | OPT+S | $71.51 | 9,002 | $643,739 | 169,519 | -5.0% |
| 2026-07-15 00:01 | 2026-07-13 | LQDA | Liquidia Corp | Moomaw Scott | Officer; Chief Commercial Officer | Biotechnology | OPT+S | $71.51 | 9,539 | $682,142 | 182,485 | -5.0% |
| 2026-07-15 00:02 | 2026-07-13 | LQDA | Liquidia Corp | Saggar Rajeev | Officer; Chief Medical Officer | Biotechnology | OPT+S | $71.51 | 9,926 | $709,816 | 171,799 | -5.5% |
| 2026-07-15 00:04 | 2026-07-13 | LQDA | Liquidia Corp | Schundler Russell | Officer; General Counsel | Biotechnology | OPT+S | $71.51 | 14,738 | $1,053,926 | 605,962 | -2.4% |
| 2026-07-15 00:05 | 2026-07-13 | LQDA | Liquidia Corp | Adair Jason | Officer; Chief Business Officer | Biotechnology | OPT+S | $71.51 | 7,863 | $562,289 | 217,126 | -3.5% |
| 2026-07-15 00:07 | 2026-07-13 | LQDA | Liquidia Corp | JEFFS ROGER | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $71.51 | 35,249 | $2,520,684 | 1,130,426 | -3.0% |
| 2026-07-15 00:08 | 2026-07-13 | LQDA | Liquidia Corp | Kaseta Michael | Officer; CFO and COO | Biotechnology | OPT+S | $71.51 | 20,430 | $1,460,966 | 345,805 | -5.6% |
| 2026-07-15 00:09 | 2026-07-13 | LQDA | Liquidia Corp | Khindri Sanjeev | Officer; Chief Development Officer | Biotechnology | SALE | $71.51 | 1,185 | $84,740 | 65,947 | -1.8% |
| 2026-07-15 00:11 | 2026-07-13 | LQDA | Liquidia Corp | Krepp Sarah | Officer; Chief Human Resource Officer | Biotechnology | OPT+S | $71.51 | 7,864 | $562,361 | 117,178 | -6.3% |
| 2026-07-14 23:00 | 2026-07-10 | ARTV | Artiva Biotherapeutics, Inc. | RA CAPITAL MANAGEMENT, L.P. | Director, 10% owner | Biotechnology | BUY | $8.96 | 21,654 | $194,039 | 16,817,573 | +0.1% |
| 2026-07-14 22:32 | 2026-07-13 | IRON | Disc Medicine, Inc. | Quisel John D | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $74.96 | 33,000 | $2,473,779 | 226,064 | -12.7% |
| 2026-07-14 22:00 | 2026-03-16 | PDEX | PRO DEX INC | Domingo Angelita Rebamontan | Director | Medical Instruments & Supplies | SALE | $47.24 | 998 | $47,146 | 18,779 | -5.0% |
| 2026-07-14 21:04 | 2026-07-09 | FDMT | 4D Molecular Therapeutics, Inc. | Kirn David | Director, Officer; See Remarks | Biotechnology | SALE | $12.64 | 58,333 | $737,411 | 884,152 | -6.2% |
| 2026-07-14 20:47 | 2026-07-10 | ALHC | Alignment Healthcare, Inc. | KAO JOHN E | Director, Officer; Chief Executive Officer | Healthcare Plans | SALE | $19.86 | 298,000 | $5,919,353 | 1,088,766 | -21.5% |
| 2026-07-14 20:34 | 2026-07-13 | UTHR | UNITED THERAPEUTICS Corp | ROTHBLATT MARTINE A | Director, Officer; Chairperson & CEO | Drug Manufacturers - Specialty & Generic | OPT+S | $535.99 | 9,500 | $5,091,950 | 40,513 | -19.0% |
| 2026-07-14 20:15 | 2026-07-10 | CGON | CG Oncology, Inc. | Mulay James | Director | Biotechnology | OPT+S | $75.16 | 24,165 | $1,816,241 | 0 | -100.0% |
| 2026-07-14 20:22 | 2026-07-10 | BCAX | Bicara Therapeutics Inc. | Mazumdar Claire | Director, Officer; Chief Executive Officer | Biotechnology | OPT+S | $28.42 | 10,000 | $284,198 | 362,152 | -2.7% |
| 2026-07-14 20:23 | 2026-07-10 | HQY | HEALTHEQUITY, INC. | Fiore Michael Henry | Officer; EVP, CHIEF COMMERCIAL OFFICER | Health Information Services | SALE | $95.00 | 2,354 | $223,630 | 52,244 | -4.3% |
| 2026-07-14 20:02 | 2026-07-13 | ANIP | ANI PHARMACEUTICALS INC | Cook Meredith | Officer; SR. VP, GENERAL COUNSEL & SEC. | Drug Manufacturers - Specialty & Generic | SALE | $81.84 | 500 | $40,920 | 77,390 | -0.6% |
| 2026-07-14 20:02 | 2026-07-10 | SOPH | SOPHiA GENETICS SA | Camblong Jurgi | Director, Officer; Executive Chairman | Health Information Services | SALE | $5.62 | 8,500 | $47,791 | 3,532,622 | -0.2% |
| 2026-07-14 20:02 | 2026-07-13 | SOPH | SOPHiA GENETICS SA | Xu Zhenyu | Officer; Chief Scientific Officer | Health Information Services | SALE | $5.70 | 4,000 | $22,819 | 610,887 | -0.7% |
| 2026-07-14 20:02 | 2026-07-13 | SOPH | SOPHiA GENETICS SA | Menu Philippe | Officer; Chief Medical Officer | Health Information Services | SALE | $5.70 | 5,000 | $28,505 | 228,387 | -2.1% |
| 2026-07-14 19:34 | 2026-07-13 | CYTK | CYTOKINETICS INC | Blum Robert I | Director, Officer; President & CEO | Biotechnology | OPT+S | $82.02 | 7,500 | $615,150 | 377,820 | -1.9% |
| 2026-07-14 16:16 | 2026-07-10 | PNTG | Pennant Group, Inc. | Guerisoli Brent | Officer; Chief Executive Officer | Medical Care Facilities | OPT+S | $41.57 | 3,159 | $131,304 | 103,829 | -3.0% |
| 2026-07-14 00:25 | 2026-07-10 | HTFL | Heartflow, Inc. | Farquhar John C.M. | Director, Officer; Chief Executive Officer | Health Information Services | SALE | $27.75 | 22,562 | $626,096 | 435,373 | -4.9% |
| 2026-07-14 00:04 | 2026-07-09 | GKOS | GLAUKOS Corp | Thurman Alex R. | Officer; SVP & CHIEF FINANCIAL OFFICER | Medical Devices | OPT+S | $155.00 | 10,000 | $1,550,000 | 43,681 | -18.6% |
| 2026-07-13 23:06 | 2026-07-09 | BOLD | Boundless Bio, Inc. | TANG KEVIN | 10% owner | Biotechnology | BUY | $2.42 | 91,585 | $222,066 | 2,790,103 | +3.4% |
| 2026-07-13 21:36 | 2026-07-09 | RCUS | Arcus Biosciences, Inc. | Jaen Juan C. | Officer; President | Biotechnology | SALE | $29.63 | 68,569 | $2,031,919 | 822,240 | -7.7% |
| 2026-07-13 21:20 | 2026-07-09 | PTCT | PTC THERAPEUTICS, INC. | Almstead Neil Gregory | Officer; CHIEF TECHNICAL OPS OFFICER | Biotechnology | OPT+S | $90.25 | 2,464 | $222,376 | 60,299 | -3.9% |
Strategic Analysis
Analyzing insider transactions within the Healthcare sector provides critical insights into institutional sentiment. When multiple executives across different companies in the same industry exhibit similar buying patterns (cluster buying), it often signals an upcoming sector-wide recovery or undervalued market conditions.
Regulatory Transparency
Our platform tracks SEC Form 4 filings in real-time. We differentiate between routine option exercises and open-market purchases to give you a clear view of "Skin in the Game". Understanding the roles of Directors vs. 10% Owners helps prioritize signals that carry the most predictive weight.
UNDERSTANDING THE DATA
FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.
TRADE DATE: The actual day the insider executed the purchase or sale in the market.
INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.
OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.
CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.
TRADE TYPES DEFINITIONS
BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.
SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.
OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.